Covaxin is one of the very few vaccines to have extensive data published, Bharat Biotech said
Hyderabad:
Emergency Use Listing (EUL) of Bharat Biotech’s COVID-19 vaccine Covaxin by the World Health Organisation (WHO) is not a long drawn process as a majority of the vaccine makers’ facilities have been audited by the global health body, Suchitra Ella, joint managing director of Bharat Biotech, said today.
“We are working closely with the World Health Organisation for the inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past,” Ms Ella said in a tweet.
Our vision seldom changes course, until our final mission is accomplished #Covaxin .We ensure to take forward WHO EUL process as per the universal regulatory guidelines & timelines for covid 19 vaccines. We will keep you posted every step ahead 👍🏼😷💉🇮🇳🙏🏼 pic.twitter.com/ePs1zj1vlk
— suchitra ella (@SuchitraElla) June 30, 2021
She further said the EUL process is a step closer to the final decision on Covaxin’s global acceptance as the rolling data is slated to begin next month.
With 10 scientific publications in 12 months, Covaxin is one of the very few vaccines to have extensive data published in globally renowned peer-reviewed journals, she said.
“Our vision seldom changes course, until our final mission is accomplished #Covaxin. We ensure to take forward WHO EUL process as per the universal regulatory guidelines & timelines for Covid-19 vaccines. We will keep you posted every step ahead,’ she tweeted
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
